Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study

被引:2
|
作者
Yuan, Guosheng [1 ]
Li, Wenli [1 ]
Zang, Mengya [1 ]
Li, Rong [1 ]
Li, Qi [1 ]
Hu, Xiaoyun [1 ]
Zhang, Qi [1 ]
Huang, Wei [2 ]
Ruan, Jian [3 ]
Pang, Huajin [4 ]
Chen, Jinzhang [1 ]
机构
[1] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, State Key Lab Organ Failure Res, Guangzhou 510515, Guangdong, Peoples R China
[2] Southern Med Univ, Shunde Hosp, Dept Oncol, Shunde 528300, Guangdong, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Med Oncol, Hangzhou 310003, Zhejiang, Peoples R China
[4] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Div Vasc & Intervent Radiol, Guangzhou 510515, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Hepatocellular carcinoma; TACE; Immune checkpoint inhibitors; Tyrosine kinase inhibitors; Overall survival; MICROENVIRONMENT; BEVACIZUMAB; SORAFENIB; TACE;
D O I
10.1007/s12672-024-00917-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives To explore the efficacy and safety of Transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC). Methods 456 patients with HCC receiving either TACE in combination with ICIs and TKIs (combination group, n = 139) or TACE monotherapy (monotherapy group, n = 317) were included from Apr 2016 to Dec 2021 in this retrospective study. We employed propensity score matching (PSM), performed 1:2 optimal pair matching, to balance potential bias. Results The mean follow-up time is 24.7 months (95% CI 22.6-26.8) for matched patients as of March 2022. After matching, the combination group achieved longer OS and PFS (median OS:21.9 vs. 16.3 months, P = 0.022; median PFS: 8.3 vs. 5.1 months, P < 0.0001) than TACE monotherapy group. The combination group had better objective response rate (ORR) and disease control rate (DCR) (ORR: 52.5% vs. 32.8%, P < 0.001; DCR: 82.7% vs. 59.6%, P < 0.001). Subgroup analysis showed that patients who received "TKIs + ICIs" after the first TACE procedure (after TACE group) achieved longer OS than those before the first TACE procedure (before TACE group) (26.8 vs. 19.2 months, P = 0.011). Adverse events were consistent with previous studies of TACE-related trials. Conclusions TACE plus TKIs and ICIs appeared to deliver longer PFS and OS in HCC patients than TACE monotherapy. "TKIs + ICIs" co-treatment within 3 months after the first TACE procedure might be a better medication strategy.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma
    Teng, Ying
    Ding, Xiaoyan
    Li, Wendong
    Sun, Wei
    Chen, Jinglong
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2022, 21
  • [22] Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world
    Xie, Diyang
    Sun, Qiman
    Wang, Xiaoying
    Zhou, Jian
    Fan, Jia
    Ren, Zhenggang
    Gao, Qiang
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (08)
  • [23] Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis
    Yang, Xue-Gang
    Sun, Yan-Yuan
    Wang, Hai-Qing
    Li, De-Shan
    Xu, Guo-Hui
    Huang, Xiao-Qi
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [24] Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study
    Zhu, Di
    Ma, Kun
    Yang, Wei
    Zhou, Hai-Feng
    Shi, Qi
    Ren, Jian-Wu
    Xie, Yu-Guan
    Liu, Sheng
    Shi, Hai-Bin
    Zhou, Wei-Zhong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] Prognostic value of platelet-to-lymphocyte ratio in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization and tyrosine kinase inhibitors plus immune checkpoints inhibitors
    Guo, Yiwan
    Wu, Wenlong
    Sun, Bo
    Guo, Tingting
    Si, Keke
    Zheng, Chuansheng
    Li, Xin
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [26] Efficacy and Safety Analysis of Transarterial Chemoembolization Plus Donafenib With or Without Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Prospective, Single-Arm, Single-Center, Phase II Clinical Study
    Li, Jinpeng
    Li, Yan
    Song, Jinlong
    Zhao, Lujun
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 1207 - 1219
  • [27] Enhanced efficacy of immune checkpoint inhibitors combined locoregional therapy and tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma: A single - center retrospective study
    Bu, Junfeng
    Li, Zihan
    Hu, Die
    Lan, Ling
    Huang, Jiwei
    Wang, Xin
    Li, Qiu
    Zhou, Jin
    Zeng, Yong
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [28] Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
    Han, Yue
    Cao, Guang
    Sun, Bin
    Wang, Jian
    Yan, Dong
    Xu, Haifeng
    Shi, Qinsheng
    Liu, Zechuan
    Zhi, Weihua
    Xu, Liang
    Liu, Bojun
    Zou, Yinghua
    BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [29] Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
    Yue Han
    Guang Cao
    Bin Sun
    Jian Wang
    Dong Yan
    Haifeng Xu
    Qinsheng Shi
    Zechuan Liu
    Weihua Zhi
    Liang Xu
    Bojun Liu
    Yinghua Zou
    BMC Gastroenterology, 21
  • [30] Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study
    Shen, Xiao
    Zhang, Jin-Xing
    Liu, Jin
    Liu, Sheng
    Shi, Hai-Bin
    Cheng, Yuan
    Zhang, Qing-Qiao
    Yin, Guo-Wen
    Zu, Qing-Quan
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 1993 - 2003